Dr Reddys Lab Q2 FY22 Results: Pharma major reports 30% growth in profit, stock up nearly 7%
Pharmaceutical major Dr Reddys Laboratories has reported healthy quarterly numbers on a year-on-year basis during the second quarter of the financial year 2021-22 (Q2FY22). Almost on all fronts, the company has reported double-digit growth during the quarter.
Pharmaceutical major Dr Reddy’s Laboratories has reported healthy quarterly numbers on a year-on-year basis during the second quarter of the financial year 2021-22 (Q2FY22). Almost on all fronts, the company has reported double-digit growth during the quarter.
Dr Reddy’s Lab consolidated profit grew by 30 per cent YoY to Rs 992 crore in Q2FY22 as compared to Rs 762.3 crore in the same period a year ago. While the company’s consolidated revenue jumped 18 per cent YoY to Rs 5763 crore as against Rs 4987 crore in the corresponding quarter a year ago.
See Zee Business Live TV Streaming Below:
Similarly, the pharma major has also reported growth in EBITDA, which is up almost 23 per cent YoY to Rs 1557 crore in the July-September quarter of FY22 versus Rs 1267 crore in Q2FY21. And, the margin has surged by 110 basis points to 27 per cent from 25.9 per cent YoY during the quarter.
The shares of Dr Reddy’s has been trading near 7 per cent higher to Rs 4878 per share on the BSE intraday today, immediate after earnings announcement. It had hit Rs 4915 per share as day’s high today on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.